Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 1
1996 3
2003 3
2004 3
2005 1
2006 2
2007 4
2008 3
2009 5
2010 3
2011 2
2012 5
2013 3
2014 5
2015 15
2016 10
2017 9
2018 8
2019 9
2020 11
2021 7
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 21039759

101 results

Results by year

Filters applied: . Clear all
Page 1
Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
Mersiades AJ, Tognela A, Haber PS, Stockler M, Lintzeris N, Simes J, McGregor I, Olver I, Allsop DJ, Gedye C, Kirby AC, Morton RL, Fox P, Clarke S, Briscoe K, Aghmesheh M, Wong N, Walsh A, Hahn C, Grimison P. Mersiades AJ, et al. BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745. BMJ Open. 2018. PMID: 30209152 Free PMC article.
Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, Olver I, Walsh A, McGregor I, Cheung Y, Tognela A, Hahn C, Briscoe K, Aghmesheh M, Fox P, Abdi E, Clarke S, Della-Fiorentina S, Shannon J, Gedye C, Begbie S, Simes J, Stockler M. Grimison P, et al. Ann Oncol. 2020 Nov;31(11):1553-1560. doi: 10.1016/j.annonc.2020.07.020. Epub 2020 Aug 13. Ann Oncol. 2020. PMID: 32801017 Free article. Clinical Trial.
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group. Poli-Bigelli S, et al. Cancer. 2003 Jun 15;97(12):3090-8. doi: 10.1002/cncr.11433. Cancer. 2003. PMID: 12784346 Free article. Clinical Trial.
Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J, Chen G, Wang D, Wang G, Lu S, Feng J, Li W, Li P, Lanzarotti C, Chessari S, Zhang L. Chang J, et al. Cancer Med. 2020 Jul;9(14):5134-5142. doi: 10.1002/cam4.3123. Epub 2020 May 30. Cancer Med. 2020. PMID: 32472742 Free PMC article. Clinical Trial.
Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J. Grunberg SM, et al. Lancet Oncol. 2009 Jun;10(6):549-58. doi: 10.1016/S1470-2045(09)70109-3. Epub 2009 May 8. Lancet Oncol. 2009. PMID: 19428297 Clinical Trial.
101 results